Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 6, 2009, Pages 381-386

  Hashine, Katsuyoshi ^a   Kusuhara, Yoshito ^a   Miura, Noriyoshi ^a   Shirato, Akitomi ^a   Sumiyoshi, Yoshiteru ^a   Kataoka, Masaaki ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Bladder preservation therapy; Chemotherapy; Invasive bladder cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; METHOTREXATE; PIRARUBICIN;

ADENOCARCINOMA; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CYSTECTOMY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEMATURIA; HERPES ZOSTER; HUMAN; HYDRONEPHROSIS; INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PYELONEPHRITIS; RADIATION DOSE; RECTUM HEMORRHAGE; SENSORY NEUROPATHY; SEPSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR VOLUME; URETER OBSTRUCTION; UROGENITAL TRACT CANCER;

AGED; COMBINED MODALITY THERAPY; HUMANS; HYDRONEPHROSIS; INFUSIONS, INTRA-ARTERIAL; MALE; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; ORGAN PRESERVATION; OSTEOCHONDROSIS; REMISSION INDUCTION; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 66449113663     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp023     Document Type: Article

References (19)

1. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-22.
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
3. Madersbacher S, Hochreiter W, Burkhand F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-6.
4. Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Sato K, Tomita Y, et al. Radical cystectomy for invasive bladder cancer: Results of multi-institutional pooled analysis. Jpn J Clin Oncol 2004;34:14-9.
5. Nishiyama H, Habuchi T, Watanabe J, Teramukai S, Tada H, Ono Y, et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: A survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol 2004;45: 176-81.
6. Sumiyoshi Y, Yokota K, Akiyama M, Inoue Y, Yoneda F, Tsujimura H, et al. Neoadjuvant intra-arterial doxorubicin chemotherapy in combination of locally advanced transitional cell carcinoma of the bladder. J Urol 1994;152:362-6.
7. Sumiyoshi Y, Hashine K, Karashima T, Kasahara Y, Inoue Y. Preliminary results of bladder preservation by concurrent intraarterial chemotherapy and radiotherapy for muscle-invasive bladder cancer. Int J Urol 1998;5:225-9.
8. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783-90.
9. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.
10. Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-6.
11. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-71.
12. George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 2004; 64:488-93.
13. de la Rosa F, Garcia-Carbonero R, Passas J, Rosino A, Lianes P, Paz-Ares L. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: Long-term followup of a prospective study. J Urol 2002;167:2413-8.
14. Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective study. Int J Urol 2000;7:41-8.
15. Hashine K, Miura N, Numata K, Shirato A, Sumiyoshi Y, Kataoka M. Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Urol 2008;15:403-6.
16. Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, et al. Clinical pharmacology of intraarterial cis-diamminedichoroplatinum (II). Cancer Res 1983;43:917-20.
17. Miyanaga N, Akaza H, Hinotsu S, Joraku A, Oikawa T, Sekido N, et al. Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Jpn J Clin Oncol 2007; 37:852-7.
18. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;21:4602-8.
19. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068-77.